Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol

[1]  F. Hayden,et al.  Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. , 2020, The Lancet. Infectious diseases.

[2]  P. Piedra,et al.  Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children , 2020, The Pediatric infectious disease journal.

[3]  M. Nakazawa,et al.  Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients. , 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[4]  V. Cosson,et al.  Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications , 2020, Antimicrobial Agents and Chemotherapy.

[5]  T. Uehara,et al.  Baloxavir Marboxil 2% Granules in Japanese Children With Influenza , 2020, The Pediatric infectious disease journal.

[6]  M. Lucero,et al.  Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study , 2020, The Lancet. Global health.

[7]  A. Monto,et al.  Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS) , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  F. Hayden,et al.  Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Wajima,et al.  Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza. , 2019, Journal of pharmaceutical sciences.

[10]  T. File,et al.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Lijun Rong,et al.  Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. , 2019, Current medicinal chemistry.

[12]  Z. Yamagata,et al.  Incidence of hospitalisation for severe complications of influenza virus infection in Japanese patients between 2012 and 2016: a cross-sectional study using routinely collected administrative data , 2019, BMJ Open.

[13]  T. File,et al.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Kazunari Hattori,et al.  In vitro characterization of baloxavir acid, a first‐in‐class cap‐dependent endonuclease inhibitor of the influenza virus polymerase PA subunit , 2018, Antiviral research.

[15]  F. Hayden,et al.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents , 2018, The New England journal of medicine.

[16]  P. Kelly,et al.  Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  S. Cusack,et al.  Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil , 2018, Scientific Reports.

[18]  T. Heikkinen,et al.  Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  A. Monto,et al.  Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study , 2018, Influenza and other respiratory viruses.

[20]  M. Okuda,et al.  Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza , 2017, Journal of pharmaceutical health care and sciences.

[21]  Alicia M. Fry,et al.  Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season , 2017, The New England journal of medicine.

[22]  S. Chevret,et al.  Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial , 2017, BMJ Open.

[23]  Hongjie Yu,et al.  Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis , 2016, PLoS medicine.

[24]  T. Uyeki,et al.  Neuraminidase Inhibitors for Critically Ill Children With Influenza , 2013, Pediatrics.

[25]  B. Cowling,et al.  Influenza Transmission in a Cohort of Households with Children: 2010-2011 , 2013, PloS one.

[26]  Kwok-Hung Chan,et al.  The population based socioeconomic burden of pediatric influenza-associated hospitalization in Hong Kong. , 2012, Vaccine.

[27]  C. Olivier.  Influenza vaccination coverage rate in children , 2012, Human vaccines & immunotherapeutics.

[28]  H. Nishiura,et al.  Household Transmission of Influenza (H1N1-2009) in Japan: Age-Specificity and Reduction of Household Transmission Risk by Zanamivir Treatment , 2011, The Journal of international medical research.

[29]  K. Reisinger,et al.  Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. , 2010, International journal of pediatric otorhinolaryngology.

[30]  M. Kiso,et al.  Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. , 2007, JAMA.

[31]  M. Kiso,et al.  Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Tashiro,et al.  Encephalitis and encephalopathy associated with an influenza epidemic in Japan. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..